Mobile App for Smoking Cessation in HIV
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new mobile app, MASP+, designed to help Black smokers with HIV quit smoking. The app features educational videos, personalized messages, and exercises to reduce anxiety and cravings. Participants will also use nicotine patches to aid in quitting. The trial seeks Black or African American adults who smoke at least 10 cigarettes daily, have HIV, and want to quit smoking. As an unphased trial, participants can contribute to innovative research that may lead to new methods for supporting smoking cessation in the community.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be receiving treatment for smoking cessation or substance use from outside the study.
What prior data suggests that this mobile app is safe for smoking cessation in Black/African American adults with HIV?
Research shows that specific safety information from studies about MASP+, a mobile app designed to help Black smokers with HIV quit smoking, is not available. This lack of detailed data means user interactions with the app remain unclear. However, as a digital tool rather than a medication, it likely poses low physical safety risks.
The app includes educational videos and personalized messages to reduce anxiety and support smoking cessation. It also features exercises to increase awareness of internal signals, such as stress or withdrawal symptoms.
Participants in this trial using MASP+ will also have access to nicotine patches, which are well-researched and commonly used for smoking cessation. Nicotine patches are generally considered safe, with mild side effects like skin irritation or dizziness being the most common.
In summary, while direct safety data for MASP+ is lacking, the app itself is unlikely to pose significant risks, especially when used alongside well-tolerated nicotine patches.12345Why are researchers excited about this trial?
Researchers are excited about the MASP+ app for smoking cessation in people with HIV because it goes beyond typical nicotine replacement therapies and basic tracking apps. Unlike standard options, MASP+ offers a personalized approach by including educational videos, tailored messages, and interoceptive exercises specifically designed for Black smokers with HIV who experience high anxiety sensitivity. This combination aims to tackle the emotional and psychological hurdles of quitting smoking, offering a more comprehensive support system compared to other apps.
What evidence suggests that this trial's treatments could be effective for smoking cessation in Black adults with HIV?
Research shows that the MASP+ app, available to participants in this trial, is designed to help Black adults with HIV quit smoking by reducing anxiety sensitivity. The app includes educational videos, personalized messages, and exercises to manage stress and nicotine withdrawal. Early results suggest these features effectively support smoking cessation in this group. Additionally, the app aids users in adhering to their HIV treatment, which is crucial for overall health. Although specific success rates are not available, the app's tailored approach for Black smokers with HIV appears promising.34678
Who Is on the Research Team?
Lorra Garey, Ph.D.
Principal Investigator
University of Houston
Michael Businelle, Ph.D.
Principal Investigator
University of Oklahoma
Are You a Good Fit for This Trial?
This trial is for Black/African American adults with HIV who smoke daily, want to quit smoking, and have moderate to high anxiety sensitivity. Participants must be over 18, motivated to quit (≥5 on a scale of 10), able to read English, and willing to use nicotine replacement therapy. Pregnant individuals or those planning pregnancy soon, non-English fluent speakers, people undergoing other treatments for smoking cessation or mental health issues are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants use the MASP+ app and receive nicotine replacement therapy to assist with smoking cessation
Follow-up
Participants are monitored for smoking abstinence and quality of life
What Are the Treatments Tested in This Trial?
Interventions
- Control
- MASP+
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Houston
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator
Baylor College of Medicine
Collaborator
University of Oklahoma
Collaborator